Dr Agarwal's Hea Q1 FY27 Results (NSE: AGARWALEYE)
Signal: Growth reaccelerated
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹614.02 Cr | 26.0% | 8.8% |
| EBIT | ₹98.51 Cr | 25.8% | |
| Net profit | ₹55.02 Cr | 44.6% | |
| EPS | ₹1.43 | 50.5% | |
| EBIT margin | 28.8% |
P&L walk
Revenue grew 26% YoY to ₹614 Cr, driven by 15.5% surgery volume growth, mature facilities revenue up 37.1%, and India revenue up 25.3%. EBITDA margin expanded 30bps YoY to 28.5% despite rising greenfield losses from 23 new surgical facilities in last six months, indicating operating discipline. PAT grew 44.6% YoY to ₹55 Cr, outpacing EBITDA growth due to lower net finance costs and controlled tax rate.
Research and educational content only. Not investment advice.